Victory Capital Management
TBPH icon

Victory Capital Management’s Theravance Biopharma TBPH Stock Holding History

Victory Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-158,470
Closed -$1.78M – 2689
2022
Q4 		$1.78M Buy
158,470
+48,120
+44% +$506K ﹤0.01% 1484
2022
Q3 		$1.12M Buy
110,350
+46,700
+73% +$438K ﹤0.01% 1678
2022
Q2 		$577K Buy
+63,650
New +$586K ﹤0.01% 1984

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Victory Capital Management's TBPH Position: Q1 2023 in Review

Victory Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2023, closing a stake of 158,470 shares — an estimated $1.78M sold.

Victory Capital Management first reported a position in TBPH in Q2 2022 and held it in 3 quarters. The position peaked at $1.78M in Q4 2022. 113 funds tracked by Wall St. Rank hold TBPH as of Q1 2023.

  • Victory Capital Management reported no remaining Theravance Biopharma position as of Q1 2023 after selling out during the quarter.
  • Victory Capital Management sold 158,470 Theravance Biopharma shares in Q1 2023, an estimated $1.78M.
  • Victory Capital Management first reported a position in Theravance Biopharma in Q2 2022 and held it in 3 quarters.
  • Victory Capital Management's Theravance Biopharma position peaked at $1.78M in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.